$GUD.TO

Knight Therapeutics Repays Amounts Outstanding Under Revolving Credit Facility

Knight Therapeutics (GUD.TO) has repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders, according to a Wednesday news release.The credit facility provides borrowing capacity of up to US$100 million, with an additional $100 million accordion feature.In June 2025, Knight drew $60 million from the credit facility to support the acquisition of the Paladin business from Endo."Today marks the one-year anniversary of the Paladin transaction and we are proud that we have repaid within a year the credit we withdrew to finance the acquisition," said Arvind Utchanah, Chief Financial Officer of Knight.

Stifel Canada Raises Knight Therapeutics Price Target to $9.50 on Q1 Beat, Outlook

Stifel Canada lifted its price target on the shares of Knight Therapeutics (GUD.TO) to C$9.50 from C$7.45 and reiterated its buy rating after the company reported a first-quarter earnings beat.Analyst Justin Keywood notes that the stock has re-rated sharply year-to-date on better than expected contribution of the Paladin/Sumitomo acquisitions and the 30% Paladin headcount reduction."Q1 sales +68.5% y/y and EBITDA, +130%, demonstrates synergies and strength is expected to continue with record setting temperatures (Super El Nino) in the LATAM region, correlated to infectious disease product demand (~35% of Knight's portfolio)," Keywood writes.Knight's runway of new launches in the coming one to two years, and "a bundling into its existing field force" could boost its long-term growth trajectory and FCF profile.Price: $7.92, Change: $-0.14, Percent Change: -1.68%

Knight Therapeutics Launches Tavalisse in Mexico

Knight Therapeutics (GUD.TO) has launched Tavalisse, its treatment for adult patients with chronic immune thrombocytopenia (ITP) in Mexico, the company said overnight Wednesday.Tavalisse is indicated for patients who have had an insufficient response to a previous treatment.Knight announced its agreement with Rigel Pharmaceuticals, in May 2022, securing exclusive rights to commercialize Tavalisse in Latin America."The launch of Tavalisse in Mexico represents an important milestone in our mission to transform lives by expanding access to innovative therapies for patients across Latin America," said Samira Sakhia, chief executive of Knight Therapeutics. "Chronic ITP continues to pose significant challenges for many patients, and we are proud to introduce a differentiated therapeutic treatment option for those who have not benefited from existing therapies. This milestone reflects our ongoing commitment to strengthening our presence in the region and providing meaningful solutions to the patients and physicians who need them."Knight Therapeutic shares closed down $0.11, to $8.05 on Wednesday on the Toronto Stock Exchange.

Knight Therapeutics Receives Approval For Tavalisse in Brazil

Knight Therapeutics (GUD.TO) has received regulatory approval from the Brazil health authorities for Tavalisse (fostamatinib disodium hexahydrate), the company said on Friday.Tavalisse is prescribed for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Tavalisse is expected to launch in Brazil in the second half of this year.Knight Therapeutic shares closed up $0.84, to $8.35 on Thursday on the Toronto Stock Exchange.

Knight Therapeutics Announced Regulatory Approval Of TAVALISSE In Brazil

Knight Therapeutics Reports Q1 Beat, Raises 2026 Revenue Guidance

Knight Therapeutics (GUD.TO) first quarter net earnings and adjusted revenue both jumped, beating forecasts, the company said on Thursday, as it raised its 2026 revenue guidance.Net income surged 503% to $13.2 million or $0.13 per share, from $2.2 million or $0.02 per share in the previous corresponding quarter. The result beat the consensus mean forecast of $0.03 per share, according to FactSet.Adjusted revenue, which excludes most one-time items, climbed 68% to $147.6 million, beating the forecast of $114.06 million. The increase was driven by the incremental revenue from the Paladin and Sumitomo portfolios, the growth of the company's promoted products, and the purchasing patterns of certain products including Ambisome deliveries to Brazil's health ministry, it said.Knight Therapeutics also increased its fiscal 2026 revenue guidance to between $510 million to $525 million in revenues up from $490 million to $510 million. Adjusted EBITDA is expected to be 15% of revenues. The higher revenue outlook is due to better performance of promoted products in several countries including Canada, Mexico and Colombia and improved forecasted LATAM currencies against the Canadian dollar.Knight shares closed down $0.04, to $7.51 on Wednesday on the Toronto Stock Exchange.

Knight Therapeutics Increased 2026 Revenue Guidance From $510M to $525M

Knight Therapeutics Q1 Revenues Up 69%

Knight Therapeutics Q1 Net Income Per Share $0.13, Compared to $0.02 a Year Earlier